Many new regenerative medicine techniques and technologies are being developed which can help stimulate repair and regeneration of injured or degenerated tissues, and we keep up to date with the latest evidence-based research and clinical studies to provide you with the latest ground-breaking interventions. Regenerative medicine utilizes several approaches for reconstructing damaged tissue and treating painful or degenerative conditions, including the use of specific types of stem cells, growth factors, signaling molecules, peptides, plasma, platelets, exosomes, biomaterials, hydrogels, and/or engineered 3D matrix constructs, along with minimally-invasive image-guided placement of these products directly at the site of injury or degeneration.
"Orthopedic surgeons are at an exciting crossroads in medicine, where biologic therapies are evolving and increasingly available. Time-tested interventions such as arthroplasty have shown good results and still have a major role to play, but newer regenerative approaches have the potential to effectively delay or reduce the requirement for such invasive procedures." --Aaron Krych and Mario Hevesi, Orthopedic Surgeons at the Mayo Clinic, International Orthopaedics, Feb 2021 .
"Orthobiologics" is a term for regenerative agents that can accelerate healing and recovery from injuries and can help avoid surgery, instead healing the root cause of the problem more naturally and more completely. For example, mesenchymal stem cells (MSCs) are multipotent cells that can be harvested from your own body and differentiate into a variety of cell types including osteoblasts (for bone), chondrocytes (for cartilage), tenocytes (for tendon), myocytes (for muscle and heart), endothelium and smooth muscle cells (for blood vessels and vascular perfusion), and possibly even neuroglial cell types (for neural tissue) [74-90]. We use highly specialized protocols to painlessly harvest, purify, and concentrate stem cells, exosomes, and growth factors from bone marrow aspirate for your particular needs, and by using your own mesenchymal stem cells you avoid the risks of stem cell rejection and immune reactions to differentiating cells.
We are also the first institute to combine stem cells with platelet-rich fibrin (PRF) to synergistically increase stem cell survival, integration, and release of growth factors at a wide variety of target sites with an array of complex image-guided injections. When injected into joints, MSCs with PRF can help patch injuries for enhanced healing and regenerate new hyaline cartilaginous matrix even in full-thickness articular cartilage defects [2-10, 24-50, 131], and this combination of stem cells + PRF is also being studied in injuries of tendon, ligament, labrum, meniscus, disc, nerve, and many other tissues [53-73].
PRF can capture your own growth factors and circulating hematopoietic and bone-marrow stem cells [11-16] and PRF uses your own cells and activated platelets to focally release growth factors such as BMP, FGF, VEGF, PDGF, eNOS, and others which are released locally over the next few days to weeks. These factors can help accelerate and strengthen tissue repair, and these further activate recruitment and differentiation of MSCs as well as expression of several tissue remodeling genes [3-7]. MSCs may also have many other good anti-inflammatory, immunomodulatory, reparative, and/or vascularization effects. These stem cells not only can help rebuild damaged tissues, but also secrete growth factors and additional signaling cues in packets known as exosomes, which can further suppress deleterious inflammatory/degenerative pathways to help kickstart cells out of a degenerative rut and back into a high-productivity regenerative phase that favors tissue healing, cellular repair, and strengthening of damaged structures. Thus in addition to powerful cell-based therapies, exosomes are also being studied as a cell-free solution for injection into or around sites of injured tissues and organs [91-102]. All these options can be administered in our clinic using minimally-invasive injections under high-resolution image-guidance for optimal repair of numerous types of injuries.
CLINICAL EVIDENCE FOR STEM CELLS:
There are several clinical studies in progress on the benefits of stem cell injections for many ailments like arthritic and damaged joints, tendon tears and connective tissue injuries, spine and spinal cord injuries, peripheral nerve injuries, stroke, brain injuries, neurodegenerative diseases, and many other forms of organ and tissue damage . For example, studies have already shown benefits and safety in knee injuries and knee osteoarthritis [37-40, 65-73]. Further clinical studies are still ongoing for several spine, nerve, brain, spinal cord, central nervous system, and other neurological conditions [42-43, 74-90, 97, 134], and autologous hematopoietic bone marrow stem cell transplants have also demonstrated some of the best effects on controlling auto-immune conditions including rheumatoid arthritis, scleroderma, Crohn's disease, and neuro-immunological diseases like multiple sclerosis by rebooting the immune system through a re-diversification of naive and regulatory immune effector cells [139-142].
Stem cells have also shown significant benefits in neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), which is characterized by degeneration of upper and lower motor neurons, with mesenchymal stem cells possibly delaying progression of this disease and even giving partial recovery of neuron function [112-116]. Bone marrow stem cells appear to be especially effective in ALS, with one clinical study showing that 87% of stem-cell treated ALS patients had at least 25% improvement in function within 6 months of autologous bone-marrow-derived mesenchymal stem cell treatment . These benefits are thought to arise at least in part due to the neurotrophic factors, growth factors, and other signaling cues that are produced and excreted by the stem cells to accelerate tissue repair [113-114, 117]. Stem cell factors such as VEGF, angiogenin, and TGF-β seem to be higher in those patients who have the best response to the stem cell therapy, and these stem cells can be delivered by epidural, intrathecal, intravenous, intranasal, intramuscular, and much more specific image-guided injections [113-114]. Mesenchymal stem cells have also been used to form a "stem cell patch" to repair degenerative disc defects, annular tears, and spina bifida defects around the spinal cord to prevent paralysis in infants and possibly even reverse damage to spinal cord and nerve function [135-138, 143-145]. One of the mechanisms of stem cell healing for herniated spinal discs and nerve compressions may be not only direct repair of the injured tissues but also suppression of the painful inflammatory immune signaling around the injury sites . Bone marrow stem cells have also been used to successfully treat traumatic brain injuries and concussions, which were shown to preserve critical brain architecture and suppress inflammatory signaling when the cells were infused intravenously . In addition, the body’s own stores of fat tissue, called subcutaneous adipose tissue (SAT), also contain multipotent stem cells of the Schwann cell class that can differentiate into both neurons and glial cells, making yet another potential source of powerful cells for potentially treating a variety of neurological injuries and conditions [118-119].
Furthermore, a recent study showed that many commercial stem cell products, including those derived from wharton's jelly, umbilical, amniotic, or other perinatal sources, actually contained very few (if any) viable stem cells at all since most die in the storage and processing . This study then compared fresh stem cells from a patient's own bone marrow and showed that these stem cells were abundant even in elderly patients and retained dramatic abilities to live, grow, proliferate, and differentiate into tissue-specific subtypes , plus these cells can build new tissue without causing an immune reaction (unlike foreign donor cells). Thus your own body is the best source for stem cell harvesting and injury repair in most cases, but those cells should be placed into the proper location with proper conditions to best repair tissue. If there is any doubt about the power of stem cells, remember that well into late age the body retains stem cells that can create entirely new offspring with perfect forms of every tissue structure-- we just need to harness the potential of our own stem cells to optimize and steer their incredible capabilities. Interestingly, animals like salamanders and axolotl are able to regenerate entire limbs, and this regenerative process is driven primarily by hematopoietic and myeloid stem cells, which in the human is the equivalent of bone marrow stem cells that drive mesenchymal cell lineages of ligament, cartilage, muscle, bone, and connective tissues . We are perhaps the only clinic that has the expertise and protocols to optimally combine these stem cells with your own purified PRF under proper conditions that maximize their survival and viability with minimal processing, then immediately inject these cells directly at the injured site under ultrasound imaging guidance for maximizing their tissue repair properties. PRF acts as a biologic glue and anchor to hold the stem cells at the injury site. Dr. McMurtrey spent several years researching stem cell cultures and applications at some of the top university labs in the world, including at the University of Oxford where his thesis on stem cells and bioregenerative tissue engineering earned the highest honor of distinction and resulted in several publications.
Depending on your needs, we can harvest stem cells from your own bone marrow with a simple needle or from stromal vascular fractions (SVF) of subcutaneous adipose fat tissue, and we use specialized protocols to maximize isolation, yield, viability, and long-term survival of the stem cells with minimal processing and immediate injection of the purified cells back into your body in the same procedure. Research has elucidated many ways that your autologous stem cells can be used to help stimulate your own natural healing, reconstruction, or repair of injured or degenerated tissues and joints such as muscle, ligaments, tendons, nerves, bones, cartilage, and fibrocartilage [2-10, 17-51, 83-90, 120-132]. Interestingly, organs like the heart and brain may also benefit from stem cell treatments, as there are also other hormones and peptides in bone marrow like osteocalcin which have been shown to enhance memory, brain function, cardiac function, fitness, metabolism, healing, and tissue remodeling after ischemic damage [120-132, 151-161]. Bone marrow stem cells have also shown promise in repairing and healing non-union fractures, failed surgeries, pseudoarthrosis, osteonecrosis, spondylolysis, pars defects, joint injuries, cartilage defects and arthritis, as well as many other complex conditions [146-153]. Other common sites for bone marrow concentrate injections include spine, disc, nerves, knee, hip, shoulder, ankle, feet, sacroiliac joint, elbows, hands, covering a wide variety of traumatic injuries and tissue defects, avulsions, fractures, tears, neuropathies, and other chronic non-healing injuries. All these procedures are best done under live image-guidance to ensure accurate and specific targeting of the injury site with appropriate localization of cells and growth factors for optimal regeneration and healing.
OVERVIEW OF SOME STEM CELL SIGNALING PATHWAYS:
Finally, the history of stem cell research is also fascinating and worth briefly covering here. The earliest concepts of stem cells arose in the early 1900s when studying the ability of bone marrow to continually produce new blood cells. Then as a graduate student in 1958, John Gurdon discovered in his research work at Oxford that mature cells retain all the information needed to make any cell type of the body encoded somewhere deep within their own DNA . Many years later, a physician named Shinya Yamanaka was pursuing his training in orthopedic surgery when he began to notice how many diseases and conditions exist that physicians actually have no ability to fix or heal (including everything from spinal cord injuries and traumatic brain injuries to orthopedic conditions and autoimmune diseases), and he lost confidence in the surgical approach and instead turned his efforts towards curing diseases from a much more thoughtful scientific approach, which ultimately resulted in one of the greatest discoveries of all time (winning a Nobel Prize in 2012): mature adult cells can in fact be reverted back to a full pluripotent stem cell state, capable of becoming any type of cell or tissue, by just introducing a few simple factors into the cell . Dr. McMurtrey has since replicated this work in his own lab, taking adult blood cells and reprogramming them back into pluripotent stem cells, then differentiating and directing them to reconstruct new 3D tissue types using a variety of biochemical, biomechanical, and nanopatterning cues [105-111].
(1) Advancing regenerative surgery in orthopaedic sports medicine: the critical role of the surgeon
(2) The Clinical Use of Human Culture-Expanded Autologous Bone Marrow Mesenchymal Stem Cells Transplanted on Platelet-Rich Fibrin Glue in the Treatment of Articular Cartilage Defects
(3) Platelet-Rich Fibrin and Its Emerging Therapeutic Benefits for Musculoskeletal Injury Treatment
(4) Platelet-Rich Fibrin Scaffolds for Cartilage and Tendon Regenerative Medicine: From Bench to Bedside
(5) From Platelet-Rich Plasma to Advanced Platelet-Rich Fibrin: Biological Achievements and Clinical Advances in Modern Surgery
(6) Leucocyte and Platelet‐rich Fibrin: a carrier of autologous multipotent cells for regenerative medicine
(7) Cytokine and Growth Factor Delivery from Implanted Platelet-Rich Fibrin Enhances Rabbit Achilles Tendon Healing
(8) Cartilage Defect Treatments: A Systematic Review and Meta-Analyses
(9) Regenerative approaches for the treatment of early OA
(10) Stem Cells in Osteochondral Tissue Engineering
(11) Circulating stem cells
(12) Peripheral blood and bone marrow hematopoietic stem cells: are they the same?
(13) Exercise-Induced Circulating Hematopoietic Stem and Progenitor Cells in Well-Trained Subjects
(14) Circulating mesenchymal stem cells
(15) Circulating Stem Cells in Physiology and Pathology - Recent Studies Published in Stem Cell Reviews and Reports
(16) Circulating Bone Marrow-Derived Osteoblast Progenitor Cells Are Recruited to the Bone-Forming Site by the CXCR4/Stromal Cell-Derived Factor-1 Pathway
(17) Clinical Trials With Mesenchymal Stem Cells: An Update
(18) Human Adipose-Derived Stem Cells with Great Therapeutic Potential
(19) Stem cells: their source, potency and use in regenerative therapies with focus on adipose-derived stem cells - a review
(20) Current Strategies to Enhance Adipose Stem Cell Function: An Update
(21) Adipose-derived mesenchymal stem cells: biology and potential applications
(22) Adult Stem Cells for Regenerative Therapy
(23) Multifaceted Characterization of Human Mesenchymal Stem Cells for Use in Regenerative Medicine
(24) Mesenchymal Stem Cells for Regenerative Medicine
(25) Regenerative Capacity of Adipose Derived Stem Cells (ADSCs), Comparison with Mesenchymal Stem Cells (MSCs)
(26) Adult mesenchymal stem cells and their exosomes: Sources, characteristics, and application in regenerative medicine
(27) Mesenchymal Stem/Stromal Cells in Regenerative Medicine: Past, Present, and Future
(28) Regenerative Cardiovascular Therapies: Stem Cells and Beyond
(29) Intraarticular injection of bone marrow-derived mesenchymal stem cells enhances regeneration in knee osteoarthritis
(30) Bone marrow mesenchymal stem cell-derived exosomes protect cartilage damage and relieve knee osteoarthritis pain in a rat model of osteoarthritis
(31) Stem cell-based therapeutic strategies for cartilage defects and osteoarthritis
(32) Stem Cell Treatment for Knee Articular Cartilage Defects and Osteoarthritis
(33) Cartilage Regeneration in Humans with Adipose Tissue-Derived Stem Cells and Adipose Stromal Vascular Fraction Cells: Updated Status
(34) Cell therapy for cartilage defects of the hip
(35) Mesenchymal stem cell therapy in the treatment of hip osteoarthritis
(36) Colony Forming Potential and Protein Composition of Commercial Umbilical Cord Allograft Products in Comparison With Autologous Orthobiologics
(37) Prospective, Single-Blind, Placebo-Controlled Trial of Bone Marrow Aspirate Concentrate for Knee Osteoarthritis
(38) Quantitative T2 MRI Mapping and 12-Month Follow-up in a Randomized, Blinded, Placebo Controlled Trial of Bone Marrow Aspiration and Concentration for Osteoarthritis of the Knees
(39) Subchondral bone or intra-articular injection of bone marrow concentrate mesenchymal stem cells in bilateral knee osteoarthritis
(40) Intraarticular injection of bone marrow-derived mesenchymal stem cells enhances regeneration in knee osteoarthritis
(41) Application of Bone Marrow-Derived Mesenchymal Stem Cells for Muscle Healing After Contusion Injury
(42) Comparison of the use of adipose-derived and bone marrow-derived stem cells for peripheral nerve regeneration in vitro and in vivo
(43) Comparative Study on Bone Marrow-Versus Adipose-Derived Stem Cells on Regeneration and Re-Innervation of Skeletal Muscle Injury
(44) Cartilage Repair With Autologous Bone Marrow Mesenchymal Stem Cell Transplantation
(45) Chondrogenic Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells: Tips and Tricks
(46) Mixed cell therapy of bone marrow-derived mesenchymal stem cells and articular cartilage chondrocytes ameliorates osteoarthritis development
(47) Mesenchymal stem cells: amazing remedies for bone and cartilage defects
(48) Use of Adult Stem Cells for Cartilage Tissue Engineering: Current Status and Future Developments
(49) Mesenchymal stem cells for cartilage regeneration
(50) GREM1 suppresses hypertrophy of engineered cartilage in vitro but not bone formation in vivo
(51) NeuroRegen Scaffolds Combined with Autologous Bone Marrow Mononuclear Cells for the Repair of Acute Complete Spinal Cord Injury: A 3-Year Clinical Study
(52) Identification of Hematopoietic Cells as the Primary Reservoir for Pro-regenerative Macrophages Required for Salamander Limb Regeneration
(53) The effect of L-PRF membranes on bone healing in rabbit tibiae bone defects: micro-CT and biomarker results
(54) Positive effects of different plasma methods on human muscle, bone, and tendon cells
(55) Influence of plasma on chondrogenic differentiation and proliferation of chondrocytes and mesenchymal stem cells
(56) Proliferation-promoting effect of plasma on human adipose-derived stem cells and human dermal fibroblasts
(57) Plasma enhances mesenchymal stem cell proliferation and chondrogenic differentiation
(58) Human plasma stimulates migration and chondrogenic differentiation of human subchondral progenitor cells
(59) Adult and umbilical cord blood-derived plasma for mesenchymal stem cell proliferation, chemotaxis, and cryo-preservation
(60) Comparison of surgically repaired Achilles tendon tears using platelet-rich fibrin matrices
(61) Treatment of tendon and muscle using plasma
(62) Plasma compared with corticosteroid injection for chronic lateral elbow tendinosis
(63) Effects of repetitive plasma application on human tenocyte proliferation
(64) Regenerative potentials of plasma enhanced by collagen in retrieving pro-inflammatory cytokine-inhibited chondrogenesis
(65) Human platelet lysate successfully promotes proliferation and subsequent chondrogenic differentiation of adipose-derived stem cells: a comparison with articular chondrocytes
(66) The Role of Intraarticular Platelet Rich Plasma Injection in Patients with Internal Knee Derangements
(67) Percutaneous injections of Platelet rich plasma for treatment of intrasubstance meniscal lesions
(68) Intra-articular Platelet-Rich Plasma Injections for Treating Knee Pain Associated with Articular Cartilage and Degenerative Meniscal Lesions
(69) Treatment of degenerative meniscal tear with intrameniscal injection of platelet rich plasma
(70) Ultrasound-Guided Meniscal Injection of Autologous Growth Factors: A Brief Report
(71) Effects of Platelet-Rich Plasma and Bone Marrow Mesenchymal Stem Cells on Meniscal Repair in the White-White Zone of the Meniscus
(72) Efficacy of Autologous Platelet-Rich Plasma Injections for Grade 3 Symptomatic Degenerative Meniscal Lesions: A 1-Year Follow-up Prospective Study
(73) Prospective Study Comparing Leukocyte-Poor Platelet-Rich Plasma Combined with Hyaluronic Acid and Autologous Microfragmented Adipose Tissue in Patients with Early Knee Osteoarthritis
(74) Bone marrow-derived mesenchymal stem cells differentiate into nerve-like cells in vitro after transfection with brain-derived neurotrophic factor gene
(75) Differentiation of Mesenchymal Stem Cells to Neuroglia: in the Context of Cell Signalling
(76) Effects of Follistatin on the Differentiation of Human Bone Marrow Mesenchymal Stem Cells into Neurons-Like Cells
(77) In vitro differentiation of human bone marrow stromal cells into neural precursor cells using small molecules
(78) Interleukin-17A promotes the differentiation of bone marrow mesenchymal stem cells into neuronal cells
(79) Bone marrow mesenchymal stem cells promote remyelination in spinal cord by driving oligodendrocyte progenitor cell differentiation via TNFα/RelB-Hes1 pathway
(80) Neuro-glial differentiation of human bone marrow stem cells in vitro
(81) Differentiation into neurons of rat bone marrow-derived mesenchymal stem cells
(82) Neurospheres Induced from Human Adipose-Derived Stem Cells as a New Source of Neural Progenitor Cells
(83) Comparative study of neural differentiation capacity of mesenchymal stromal cells from different tissue sources: An approach for use in neural regeneration therapies
(84) Stem cell therapy for nerve injury
(85) Combining cell therapy with human autologous Schwann cell and bone marrow-derived mesenchymal stem cell in patients with subacute complete spinal cord injury
(86) Stem cell therapies for acute spinal cord injury in humans: a review
(87) Adipose Tissue and Mesenchymal Stem Cells: State of the Art and Lipogems Technology Development
(88) Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: A Phase I clinical trial
(89) A clinical trial report of autologous bone marrow-derived mesenchymal stem cell transplantation in patients with spinal cord injury
(90) A Phase III Clinical Trial Showing Limited Efficacy of Autologous Mesenchymal Stem Cell Therapy for Spinal Cord Injury
(91) Biology and therapeutic potential of mesenchymal stem cell-derived exosomes
(92) The biology , function , and biomedical applications of exosomes
(93) MSC-Derived Exosomes for Cell-Free Therapy
(94) Therapeutic application of exosomes in ischaemic stroke
(95) Mesenchymal stem cell-derived exosomes: therapeutic opportunities and challenges for spinal cord injury
(96) Neural stem cell-derived exosomes facilitate spinal cord functional recovery after injury by promoting angiogenesis
(97) Exosomes as a Promising Therapeutic Strategy for Peripheral Nerve Injury
(98) Therapeutic Application of Exosomes in Inflammatory Diseases
(99) Exosomes: biology, therapeutic potential, and emerging role in musculoskeletal repair and regeneration
(100) Therapeutic potential of exosomes in rotator cuff tendon healing
(101) Exosomes in osteoarthritis and cartilage injury: advanced development and potential therapeutic strategies
(102) Mutant SRF and YAP synthetic modified mRNAs drive cardiomyocyte nuclear replication
(103) John Gurdon - Nobel Prize Biographical Essay
(104) Shinya Yamanaka - Nobel Prize Biographical Essay
(105) Analytic Models of Oxygen and Nutrient Diffusion, Metabolism Dynamics, and Architecture Optimization in Three-Dimensional Tissue Constructs with Applications and Insights in Cerebral Organoids
(106) Patterned and functionalized nanofiber scaffolds in three-dimensional hydrogel constructs enhance neurite outgrowth and directional control
(107) Novel advancements in three-dimensional neural tissue engineering and regenerative medicine
(108) Roles of Diffusion Dynamics in Stem Cell Signaling and Three-Dimensional Tissue Development
(109) Multi-compartmental biomaterial scaffolds for patterning neural tissue organoids in models of neurodevelopment and tissue regeneration
(110) Organoids and Mini-Organs: Elements of organoid design
(111) Co-Electrospun Silk Fibroin and Gelatin Methacryloyl Sheet Seeded with Mesenchymal Stem Cells for Tendon Regeneration
(112) The Safety and Efficacy of Stem Cell Therapy as an Emerging Therapy for ALS: A Systematic Review of Controlled Clinical Trials
(113) Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials
(114) Amyotrophic lateral sclerosis: promising therapeutic outcome–not far away?
(115) Mesenchymal Stem Cells: A Potential Therapeutic Approach for Amyotrophic Lateral Sclerosis?
(116) Stem cell treatments for amyotrophic lateral sclerosis: a critical overview of early phase trials
(117) Cytoplasm or Supernatant: Where Is the Treasury of the Bioactive Antiaging Factor from Mesenchymal Stem Cells?
(118) Schwann cells in the subcutaneous adipose tissue have neurogenic potential and can be used for regenerative therapies
(119) Fat could hold key to stem cell treatments for Parkinson's disease
(120) Maternal and offspring pools of osteocalcin influence brain development and functions
(120) Mediation of the Acute Stress Response by the Skeleton
(122) Osteocalcin Signaling in Myofibers Is Necessary and Sufficient for Optimum Adaptation to Exercise
(123) Using Stem Cell Therapies to Reestablish Osteogenic Capability for Bone Regeneration
(124) Adult Stem Cells for Bone Regeneration and Repair
(125) Prospect of Stem Cell Therapy and Regenerative Medicine in Osteoporosis
(126) The Current Perspectives of Stem Cell Therapy in Orthopedic Surgery
(127) BMP-9 induced osteogenic differentiation of mesenchymal stem cells: molecular mechanism and therapeutic potential
(128) Clinical evaluation following the percutaneous transplantation of allogenic bone marrow-derived mesenchymal stem cells (aBM-MSC) in dogs affected by vertebral compression fracture
(129) Mesenchymal Stem Cells for Bone Repair and Metabolic Bone Diseases
(130) Systemic Adult Stem Cell Therapy for Osteoporosis-Related Vertebral Compression Fractures
(131) Mesenchymal stem cells: amazing remedies for bone and cartilage defects
(132) Lipid availability determines skeletal progenitor cell fate via SOX9
(133) A new neutrophil subset promotes CNS neuron survival and axon regeneration
(134) CIRM Clinical Trials
(135) World-first stem cell therapy trial treats spina bifida before birth
(136) Cellular Therapy for In Utero Repair of Myelomeningocele - The CuRe Trial (CuRe)
(137) Bone mesenchymal stem cells attenuate radicular pain by inhibiting microglial activation in a rat noncompressive disk herniation model
(138) Treatment of Severe Adult Traumatic Brain Injury Using Bone Marrow Mononuclear Cells
(139) Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases
(140) Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations
(141) Stem cell therapy can safely slow progression of relapsing-remitting MS
(142) Stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study
(143) Bone marrow mesenchymal stem cells and exercise restore motor function following spinal cord injury by activating PI3K/AKT/mTOR pathway
(144) Mesenchymal Stem Cell Transplantation: Neuroprotection and Nerve Regeneration After Spinal Cord Injury
(145) Bone marrow mesenchymal stem cells (BMSCs) improved functional recovery of spinal cord injury partly by promoting axonal regeneration
(146) Stem Cell Therapy in the Management of Fracture Non-Union – Evaluating Cellular Mechanisms and Clinical Progress.
(147) The role of stem cells in fracture healing and nonunion.
(148) Percutaneous injection of bone marrow mesenchymal stem cells for ankle non-unions.
(149) Adult Stem Cells for Bone Regeneration and Repair.
(150) Stem cell therapy for fracture non-union: The current evidence from human studies.
(151) A systematic review of the clinical applications and complications of bone marrow aspirate concentrate in management of bone defects and nonunions.
(152) Application of bone marrow mesenchymal stem cells to the treatment of osteonecrosis of the femoral head.
(153) Cotransplantation of mesenchymal stem cells and endothelial progenitor cells for treating steroid-induced osteonecrosis of the femoral head.
(154) Effects of intravenous administration of allogenic bone marrow- and adipose tissue-derived mesenchymal stem cells on functional recovery and brain repair markers in experimental ischemic stroke
(155) Bone marrow-derived cells contribute to infarct remodelling.
(156) Randomized Trial of Targeted Transendocardial Mesenchymal Precursor Cell Therapy in Patients With Heart Failure.
(157) Bone Marrow Mesenchymal Stem Cells for Heart Failure Treatment: A Systematic Review and Meta-Analysis.
(158) The therapeutic potential of mesenchymal stem cells for cardiovascular diseases.
(159) Mesenchymal stem cell mediates cardiac repair through autocrine, paracrine and endocrine axes.
(160) Mesenchymal Stem Cells in Cardiology.
(161) Mesenchymal stem cells and cardiac repair.
-----AAMI © 2021 All Rights Reserved
*Disclaimer: The information presented here is for informational use and cites the ongoing cutting-edge research and medical advancements on these relevant topics. There are many treatments, interventions, and protocols routinely practiced in medicine and surgery which the FDA has not studied nor formally approved yet which have demonstrated overwhelming evidence of efficacy and clinical benefit. The FDA does not regulate the practice of medicine but rather regulates medical marketing of devices and drugs. The FDA does not conduct clinical trials or attempt to discover new treatments, but rather requires companies or other entities to fund marketing approvals. Breakthrough technologies typically require years to decades of research work to optimize the technology and collect enough data to prove efficacy and superiority, which in some cases can optionally be submitted to the FDA if there is sufficient financial backing to market a specific product or drug. Thus the FDA has not yet studied, evaluated, or formally approved many regenerative therapies currently practiced by many of the top physicians and surgeons in the United States and around the world. Some therapies, products, or interventions may still be considered investigational or "off-label" even with substantial evidence of efficacy, and many different applications of regenerative therapies continue to be researched by our institute and other top institutions around the world. We seek to always provide the highest-quality evidence-based care to our patients, which may include FDA-approved therapies as well as additional investigational or alternative therapies. We always discuss potential risks and benefits of all these options. The rapid evolution and advancement of medicine demands that physicians continually update their knowledge and practice techniques to adapt to future improvements and advancing technologies. These statements have not been evaluated by the FDA, and the treatments and products presented here are for informational purposes and not intended or guaranteed to diagnose, treat, cure, or prevent any specific disease or condition. All injuries and conditions should be formally evaluated by a knowledgeable medical professional whereby standard treatments and/or additional therapeutic interventions may be considered with the diagnosis and treatment plan.